Retroperitoneal lymphadenectomy in staging and treatment: The development of nerve-sparing techniques

J. P. Donohue, R. S. Foster

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Currently, where available and widely practiced, nerve-sparing RPLND offers the least toxic and safest alternative in management of clinical stage I nerve-sparing germ cell tumor. Twenty-six percent to 30% of such cases are found to be node positive and, if no adjuvant chemotherapy is elected, two thirds do not relapse; those who do are uniformly rescued by chemotherapy. The 70% who are node negative have no long-term toxicity and do better in quality of life studies than their surveillance counterparts. Also, risk- benefit and cost-benefit studies support the competitive position of RPLND vis-a-vis the other options. Nonetheless, it is fair to say there are several options for management of clinical stage I nonseminomatous germ cell tumors that, when well applied, work well. Their choice depends on regional factors related to availability and experience.

Original languageEnglish (US)
Pages (from-to)461-468
Number of pages8
JournalUrologic Clinics of North America
Volume25
Issue number3
DOIs
StatePublished - Jan 1 1998

Fingerprint

Lymph Node Excision
Cost-Benefit Analysis
Germ Cell and Embryonal Neoplasms
Poisons
Adjuvant Chemotherapy
Quality of Life
Recurrence
Drug Therapy
Therapeutics
Nonseminomatous germ cell tumor

ASJC Scopus subject areas

  • Urology

Cite this

Retroperitoneal lymphadenectomy in staging and treatment : The development of nerve-sparing techniques. / Donohue, J. P.; Foster, R. S.

In: Urologic Clinics of North America, Vol. 25, No. 3, 01.01.1998, p. 461-468.

Research output: Contribution to journalArticle

@article{f21a90ce649d4d80974d7f89850c8ec1,
title = "Retroperitoneal lymphadenectomy in staging and treatment: The development of nerve-sparing techniques",
abstract = "Currently, where available and widely practiced, nerve-sparing RPLND offers the least toxic and safest alternative in management of clinical stage I nerve-sparing germ cell tumor. Twenty-six percent to 30{\%} of such cases are found to be node positive and, if no adjuvant chemotherapy is elected, two thirds do not relapse; those who do are uniformly rescued by chemotherapy. The 70{\%} who are node negative have no long-term toxicity and do better in quality of life studies than their surveillance counterparts. Also, risk- benefit and cost-benefit studies support the competitive position of RPLND vis-a-vis the other options. Nonetheless, it is fair to say there are several options for management of clinical stage I nonseminomatous germ cell tumors that, when well applied, work well. Their choice depends on regional factors related to availability and experience.",
author = "Donohue, {J. P.} and Foster, {R. S.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1016/S0094-0143(05)70035-5",
language = "English (US)",
volume = "25",
pages = "461--468",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Retroperitoneal lymphadenectomy in staging and treatment

T2 - The development of nerve-sparing techniques

AU - Donohue, J. P.

AU - Foster, R. S.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Currently, where available and widely practiced, nerve-sparing RPLND offers the least toxic and safest alternative in management of clinical stage I nerve-sparing germ cell tumor. Twenty-six percent to 30% of such cases are found to be node positive and, if no adjuvant chemotherapy is elected, two thirds do not relapse; those who do are uniformly rescued by chemotherapy. The 70% who are node negative have no long-term toxicity and do better in quality of life studies than their surveillance counterparts. Also, risk- benefit and cost-benefit studies support the competitive position of RPLND vis-a-vis the other options. Nonetheless, it is fair to say there are several options for management of clinical stage I nonseminomatous germ cell tumors that, when well applied, work well. Their choice depends on regional factors related to availability and experience.

AB - Currently, where available and widely practiced, nerve-sparing RPLND offers the least toxic and safest alternative in management of clinical stage I nerve-sparing germ cell tumor. Twenty-six percent to 30% of such cases are found to be node positive and, if no adjuvant chemotherapy is elected, two thirds do not relapse; those who do are uniformly rescued by chemotherapy. The 70% who are node negative have no long-term toxicity and do better in quality of life studies than their surveillance counterparts. Also, risk- benefit and cost-benefit studies support the competitive position of RPLND vis-a-vis the other options. Nonetheless, it is fair to say there are several options for management of clinical stage I nonseminomatous germ cell tumors that, when well applied, work well. Their choice depends on regional factors related to availability and experience.

UR - http://www.scopus.com/inward/record.url?scp=0031904482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031904482&partnerID=8YFLogxK

U2 - 10.1016/S0094-0143(05)70035-5

DO - 10.1016/S0094-0143(05)70035-5

M3 - Article

C2 - 9728215

AN - SCOPUS:0031904482

VL - 25

SP - 461

EP - 468

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 3

ER -